title: Antibiotic resistance in orthopaedic surgery: acute knee prosthetic joint infections due to extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.
abstract: The aim of this study was to describe the prevalence and characteristics of knee prosthetic joint infections due to extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. From 2000 to 2007, 132 infections out of 5,076 arthroplasties (2.6%) were registered. Seven out of 132 infections (5.3%) were due to ESBL-producing Enterobacteriaceae, Escherichia coli in six cases and Klebsiella pneumoniae in one. Open debridement and retention of the implant was the first surgical approach and all patients received intravenous carbapenems. Relapse was documented in four cases and remission in three. Therefore, debridement without prosthesis removal was associated with a high failure rate.
authors.affiliation: Department of Orthopaedic Surgery, Knee Unit, Hospital Clínic of Barcelona, Villaroel 170, Barcelona, Spain.
authors.forename: J C
authors.initials: JC
authors.lastname: Martínez-Pastor
authors.forename: F
authors.initials: F
authors.lastname: Vilchez
authors.forename: C
authors.initials: C
authors.lastname: Pitart
authors.forename: J M
authors.initials: JM
authors.lastname: Sierra
authors.forename: A
authors.initials: A
authors.lastname: Soriano
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000627:therapeutic use; D003646:Debridement; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000601:surgery; D005260:Female; D006801:Humans; D007719:Knee Joint / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D016459:Prosthesis-Related Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000601:surgery; D018440:beta-Lactam Resistance
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems
references.citation: Chemotherapy. 1999 Jan-Feb;45(1):28-36
references.pmid: 9876207
references.citation: Clin Infect Dis. 2006 Apr 1;42(7):925-34
references.pmid: 16511754
references.citation: Clin Microbiol Infect. 2006 Sep;12(9):930-3
references.pmid: 16882303
references.citation: Int J Antimicrob Agents. 2004 Dec;24(6):585-91
references.pmid: 15555882
references.citation: Antimicrob Agents Chemother. 2004 Apr;48(4):1175-87
references.pmid: 15047518
references.citation: Antimicrob Agents Chemother. 1995 Nov;39(11):2423-5
references.pmid: 8585720
references.citation: Clin Microbiol Infect. 2003 Jul;9(7):708-12
references.pmid: 12925113
references.citation: Am J Med. 2006 Nov;119(11):993.e7-10
references.pmid: 17071171
references.citation: Clin Microbiol Infect. 2006 Oct;12(10):1030-3
references.pmid: 16961643
references.citation: Emerg Infect Dis. 2003 Aug;9(8):1024-5
references.pmid: 12971376
references.citation: J Infect. 2007 Jul;55(1):1-7
references.pmid: 17343916
references.citation: JAMA. 1998 May 20;279(19):1537-41
references.pmid: 9605897